Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Navigating the Difficulties of Nutrition During Cancer Care as a Nurse

April 26, 2025
By Claudia Aguilar Clancy, RN, FNP-C
News
Video
Conference|Oncology Nursing Society’s Annual Meeting (ONS)

“Food is powerful, and [patients] need fuel,” said Claudia Aguilar Clancy, RN, FNP-C, about ensuring patients receive the nutrition they require during cancer treatment.

Claudia Aguilar Clancy, RN, FNP-C, stated that addressing the nutritional needs of patients with various types of cancer can be difficult because it depends on several things, such as where the tumor developed and whether the patient requires a feeding tube.

During a conversation with CancerNetwork® at the 2025 Oncology Nursing Society Congress, Clancy, a nurse practitioner at Texas Oncology, discussed the complexities of helping patients meet their dietary and nutritional needs during cancer care. For those who have to use a feeding tube, soft foods and pureed foods are commonly used; Clancy stated that there is a long list of high-protein and soft food options that she shows her patients so they receive “the best fuel possible.”

Additionally, the type of treatment that a patient receives factors into what they can and cannot eat. If a patient receives radiation therapy directed at the gastrointestinal tract, Clancy will not serve that patient foods with high amounts of fiber because it may lead to more diarrhea or nausea.

The goal is not only to supply food that mitigates adverse effects (AEs) but also to provide a patient with the strength to get through their treatments.


Transcript:

I love my head and neck population. They are challenging, and they’re unique because it depends on where the tumor starts and it depends on where the feeding tube is going to go. Is it going to be in the stomach? Is it going to be in the jejunum, [also known as] the J-tube? If they can eat some [food], normally we assess, “OK, do they have a feeding tube? Can they eat orally?” If they cannot, then that’s when the formulas are obtained and [they get] soft foods and pureed foods. I give them a big list of all those [items] that are high protein but soft. They’re getting the best fuel possible.

Then we have our patients who don’t have a feeding tube, and those patients can eat. During radiation, depending on where the radiation is, if it’s a [gastrointestinal] tract radiation location, then we have to think about lower-fiber [foods] even though fiber is good, but at that particular time, it can cause more diarrhea and more of those [AEs] that we don’t want them to have. It could also cause a little more nausea and things like that.

We have to see what the diagnosis is to tailor the nutrition part of it so that they can be successful and have low [AEs] because of food but also have food that is going to help them get through the radiation. Food is powerful, and they need fuel. It’s a challenge because at that time, they don’t want to eat, but they have to eat.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.

Top Trials From the 2025 ASCO and EHA Meetings

Julie M. Vose, MD, MBA
July 25th 2025
Article

The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Improved Outcomes With Nivolumab May Be Associated With CD163+ Macrophages in Metastatic RCC

Improved Outcomes With Nivolumab May Be Associated With CD163+ Macrophages in Metastatic RCC

Ashley Chan
July 21st 2025
Article

New research suggests high levels of CD163-positive tumor-associated macrophages may significantly improve nivolumab efficacy in metastatic RCC.


The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.

New Peritoneal Surface Malignancy Guidelines Aim to Improve Unity Among Oncologists

Tim Cortese
July 21st 2025
Article

The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.

Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.

Top Trials From the 2025 ASCO and EHA Meetings

Julie M. Vose, MD, MBA
July 25th 2025
Article

The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Improved Outcomes With Nivolumab May Be Associated With CD163+ Macrophages in Metastatic RCC

Improved Outcomes With Nivolumab May Be Associated With CD163+ Macrophages in Metastatic RCC

Ashley Chan
July 21st 2025
Article

New research suggests high levels of CD163-positive tumor-associated macrophages may significantly improve nivolumab efficacy in metastatic RCC.


The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.

New Peritoneal Surface Malignancy Guidelines Aim to Improve Unity Among Oncologists

Tim Cortese
July 21st 2025
Article

The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.